EGFR and non-small cell lung carcinoma: A mata analysis including five clinical trials showed that ICI treatment significantly prolonged NSCLC patients with wild-type EGFR (95% CI = 0.60 - 0.75; P < 0.001), but ICI treatment did not prolong OS in the EGFR mutation subgroup (95% CI = 0.80 - 1.53; P = 0.540) 9.